特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
941390

腎臓がん治療の世界市場:治療クラス別、薬理活性クラス別、地域別の分析、シェア、トレンド、市場規模、予測:2020年~2026年

Kidney Cancer Market, by Therapeutic Class, by Pharmacologic Class, and By Geography - Analysis, Share, Trends, Size, & Forecast From 2020 - 2026

出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 180 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.49円
腎臓がん治療の世界市場:治療クラス別、薬理活性クラス別、地域別の分析、シェア、トレンド、市場規模、予測:2020年~2026年
出版日: 2020年06月01日
発行: AnalystView Market Insights
ページ情報: 英文 180 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の腎臓がん治療市場は、2019年の時点で53億1,000万米ドルとなっており、2020年から2026年まで5.1%のCAGRで成長を続ける見通しです。

当レポートは、世界の腎臓がん治療市場を調査したもので、市場のトレンド、業界の分析、治療クラス別、薬理活性クラス別、地域別の分析、主要ベンダーの分析などの情報を提供しています。

目次

第1章 市場の概要

  • 調査範囲
  • 前提条件と調査方法

第2章 エグゼクティブサマリー

  • 市場区分
    • 治療クラス別
    • 薬理活性クラス別
    • 地域別
  • 競合状況の考察

第3章 市場の主なトレンド

  • 市場成長促進要因
    • 市場成長促進要因の影響分析
  • 市場成長阻害要因
    • 市場成長阻害要因の影響分析
  • 市場機会
  • 今後のトレンド

第4章 業界の分析

  • ポーターのファイブフォース分析
  • マーケティング戦略分析
  • 成長見通しのマッピング
  • 規制の枠組みの分析
  • COVID-19パンデミックの影響分析

第5章 市場の現状

  • 市場シェア分析
  • 技術革新を担っている主な企業
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第6章 市場分析:治療上のクラス

  • 概要
    • セグメントシェア分析
  • 標的療法
  • 免疫療法
  • その他

第7章 市場分析:薬理活性クラス別

  • 概要
    • セグメントシェア分析
  • サイトカイン免疫療法(IL-2)
  • 血管新生阻害剤
  • ラパマイシン哺乳類標的(mTOR)阻害剤
  • モノクローナル抗体
  • その他

第8章 市場分析:地域別

  • イントロダクション
    • セグメントシェア分析
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • その他
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • 韓国
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
    • その他
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第9章 ベンダーの分析

  • Bayer Healthcare
    • 会社のスナップショット
    • 財務実績
    • 製品のベンチマーク
    • 戦略的取り組み
  • Novartis AG
  • Prometheus Labs
  • Eisai Co., Ltd.
  • Bristol-Myers Squibb
  • Genentech (Roche)
  • Exelixis, Inc.
  • Pfizer, Inc.

第10章 アナリストの見解

第11章 付録

  • 調査手法
  • 参考文献
  • 略語
  • 免責事項
  • お問い合わせ
図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Kidney Cancer Drugs market: Therapeutic Class Snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Therapeutic Class
  • TABLE Global Kidney Cancer Drugs market, by Therapeutic Class 2015-2026 (USD Million)
  • TABLE Kidney Cancer Drugs market: Pharmacological Class Snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Pharmacological Class
  • TABLE Global Kidney Cancer Drugs market, by Pharmacological Class 2015-2026 (USD Million)
  • TABLE Kidney Cancer Drugs market: Regional snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Kidney Cancer Drugs market, by Region 2015-2026 (USD Million)
  • TABLE North America Kidney Cancer Drugs market, by Country, 2015-2026 (USD Million)
  • TABLE North America Kidney Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)
  • TABLE North America Kidney Cancer Drugs market, by Pharmacological Class, 2015-2026 (USD Million)
  • TABLE Europe Kidney Cancer Drugs market, by country, 2015-2026 (USD Million)
  • TABLE Europe Kidney Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)
  • TABLE Europe Kidney Cancer Drugs market, by Pharmacological Class, 2015-2026 (USD Million)
  • TABLE Asia Pacific Kidney Cancer Drugs market, by country, 2015-2026 (USD Million)
  • TABLE Asia Pacific Kidney Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)
  • TABLE Asia Pacific Kidney Cancer Drugs market, by Pharmacological Class, 2015-2026 (USD Million)
  • TABLE Latin America Kidney Cancer Drugs market, by country, 2015-2026 (USD Million)
  • TABLE Latin America Kidney Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)
  • TABLE Latin America Kidney Cancer Drugs market, by Pharmacological Class, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Kidney Cancer Drugs market, by country, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Kidney Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Kidney Cancer Drugs market, by Pharmacological Class, 2015-2026 (USD Million)

List of Figures

  • FIGURE Kidney Cancer Drugs market segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2018
  • FIGURE Therapeutic Class segment market share analysis, 2019 & 2026
  • FIGURE Therapeutic Class segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Targeted Therapy segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Immunotherapy segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Pharmacological Class segment market share analysis, 2019 & 2026
  • FIGURE Pharmacological Class segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Cytokine Immunotherapy (IL-2) segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Angiogenesis Inhibitors segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Mammalian Target of Rapamycin (mTOR) Inhibitors segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Monoclonal Antibodies segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Regional segment market share analysis, 2019 & 2026
  • FIGURE Regional segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE North America Kidney Cancer Drugs market share and leading players, 2018
  • FIGURE Europe Kidney Cancer Drugs market share and leading players, 2018
  • FIGURE Asia Pacific Kidney Cancer Drugs market share and leading players, 2018
  • FIGURE Latin America Kidney Cancer Drugs market share and leading players, 2018
  • FIGURE Middle East and Africa Kidney Cancer Drugs market share and leading players, 2018
  • FIGURE North America Kidney Cancer Drugs market share analysis by country, 2018
  • FIGURE U.S. Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Canada Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Europe Kidney Cancer Drugs market share analysis by country, 2018
  • FIGURE Germany Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Spain Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Italy Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE UK Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE France Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of the Europe Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Asia Pacific Kidney Cancer Drugs market share analysis by country, 2018
  • FIGURE India Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE China Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Japan Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE South Korea Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Singapore Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of APAC Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Latin America Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Latin America Kidney Cancer Drugs market share analysis by country, 2018
  • FIGURE Brazil Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Mexico Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Argentina Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of LATAM Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Middle East and Africa Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Middle East and Africa Kidney Cancer Drugs market share analysis by country, 2018
  • FIGURE Saudi Arabia Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE United Arab Emirates Kidney Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
目次

REPORT HIGHLIGHT

Kidney cancer market was valued at USD 5.31 billion by 2019, growing with 5.1% CAGR during the forecast period, 2020-2026

Market Dynamics

Kidney cancer is among the most common cancer observed these days, which falls within the top ten most common cancer in both female and male. As per a study by the American Cancer Society (ACS), nearly 64,000 adults are diagnosed with kidney cancer every year in the U.S. of which about 64% are male. In addition, the average age of diagnosis is 64 years and above. Thus, growing prevalence of kidney cancer owing to adoption of unhealthy lifestyles such as less physical activity, drinking, and smoking and approval of novel drugs for treatment are the major factors driving the growth of global kidney cancer drugs market.

In addition, immunotherapies would arise as an opportunity for innovators in the market. Furthermore, a huge number of the undiagnosed patient base in the untapped geographies will likely create lucrative opportunities for the market vendors. However, increasing preference for generic drugs and high costs associated with branded drugs to treat cancer are expected to hamper the market growth in the coming future.

Segment Takeaway

Targeted therapy will be high in demand owing to the rising preference of immune-oncologic agents and novel immunotherapies. Several forms of cancer treatment methods have been instigated amongst the currently approved drugs such as cytokine therapy, immune modulation therapy, mTOR inhibitor, and VEGF inhibitor. Thus, the targeted therapy segment is estimated to hold the largest market share in the projected timeframe. In addition, it is also predicted that the combination regiments of PD-1 inhibitors will be introduced in the first place to target major unmet needs such as maintaining the quality of life, enhancing progression-free survival, and overcoming tumour resistance.

The drug development for kidney cancer focuses on using novel treatments as kidney cancer is not responsive to traditional treatments of cancer treatments. PD-L1 and PD-1 inhibitors represent a model shift in the treatment of kidney cancer. Several PD-L1 and PD-1 agents with fresh MoAs are in early stages of development and are being estimated both as monotherapy and with immune-oncology agents that are already approved. Thus, it is estimated that mTOR inhibitors will be the fastest-growing segment during the forecast period.

REGIONAL TAKEAWAY

Presently, the North America region is estimated to subjugate the global kidney cancer drugs market trailed by Europe and the Asia Pacific. Presence of large patient pool & major market vendors and well-established healthcare infrastructure is driving the growth of North America kidney cancer drugs market. On the other hand, growing prevalence of kidney cancer and increasing government initiatives to enhance healthcare facilities in the developing economies of Asia Pacific will help the region to grow at the fastest rate during the forecast period.

In kidney cancer therapeutics, biosimilar development is gaining popularity as a promising market opportunity. The prominent players of the industry are adopting several strategies such as commercial expansion, clinical collaborations, and novel product development to increase their market share. These players functioning in the global market include:

  • Bayer Healthcare
  • Novartis AG
  • Prometheus Labs
  • Eisai Co., Ltd.
  • Bristol-Myers Squibb
  • Genentech (Roche)
  • Exelixis
  • Pfizer, Inc.

The market size and forecast for each segment and sub-segments has been considered as below:

  • Historical Year - 2015 to 2018
  • Base Year - 2019
  • Estimated Year - 2020
  • Projected Year - 2026

TARGET AUDIENCE

  • Traders, Distributors, and Suppliers
  • Manufacturers
  • Government and Regional Agencies
  • Research Organizations
  • Consultants
  • Distributors

Scope of the Report

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL KIDNEY CANCER MARKET, BY THERAPEUTIC CLASS

  • Targeted Therapy
  • Immunotherapy
  • Others

GLOBAL KIDNEY CANCER MARKET, BY PHARMACOLOGICAL CLASS

  • Cytokine Immunotherapy (IL-2)
  • Angiogenesis Inhibitors
  • Mammalian Target of Rapamycin (mTOR) Inhibitors
  • Monoclonal Antibodies
  • Others

GLOBAL KIDNEY CANCER MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Singapore
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Rest of MEA

TABLE OF CONTENT

1. KIDNEY CANCER DRUGS MARKET OVERVIEW

  • 1.1. Study Scope
  • 1.2. Assumption and Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Market Snippet
    • 2.1.1. Market Snippet by Therapeutic Class
    • 2.1.2. Market Snippet by Pharmacological Class
    • 2.1.3. Market Snippet by Region
  • 2.2. Competitive Insights

3. KIDNEY CANCER DRUGS KEY MARKET TRENDS

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. KIDNEY CANCER DRUGS INDUSTRY STUDY

  • 4.1. Porter's Five Forces Analysis
  • 4.2. Marketing Strategy Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis
  • 4.5. COVID-19 Impact Analysis
    • 4.5.1. Pre-COVID-19 Impact Analysis
    • 4.5.2. Post-COVID-19 Impact Analysis

5. KIDNEY CANCER DRUGS MARKET LANDSCAPE

  • 5.1. Market Share Analysis
  • 5.2. Key Innovators
  • 5.3. Breakdown Data, by Key manufacturer
    • 5.3.1. Established Player Analysis
    • 5.3.2. Emerging Player Analysis

6. KIDNEY CANCER DRUGS MARKET - BY THERAPEUTIC CLASS

  • 6.1. Overview
    • 6.1.1. Segment Share Analysis, By Therapeutic Class, 2019 & 2026 (%)
  • 6.2. Targeted Therapy
    • 6.2.1. Overview
    • 6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 6.3. Immunotherapy
    • 6.3.1. Overview
    • 6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 6.4. Others
    • 6.4.1. Overview
    • 6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

7. KIDNEY CANCER DRUGS MARKET - BY PHARMACOLOGICAL CLASS

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Pharmacological Class, 2019 & 2026 (%)
  • 7.2. Cytokine Immunotherapy (IL-2)
    • 7.2.1. Overview
    • 7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.3. Angiogenesis Inhibitors
    • 7.3.1. Overview
    • 7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.4. Mammalian Target of Rapamycin (mTOR) Inhibitors
    • 7.4.1. Overview
    • 7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.5. Monoclonal Antibodies
    • 7.5.1. Overview
    • 7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.6. Others
    • 7.6.1. Overview
    • 7.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

8. KIDNEY CANCER DRUGS MARKET- BY GEOGRAPHY

  • 8.1. Introduction
    • 8.1.1. Segment Share Analysis, By Region, 2019 & 2026 (%)
  • 8.2. North America
    • 8.2.1. Overview
    • 8.2.2. Key Manufacturers in North America
    • 8.2.3. North America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.2.4. North America Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 8.2.5. North America Market Size and Forecast, By Pharmacological Class, 2015 - 2026 (US$ Million)
    • 8.2.6. U.S.
      • 8.2.6.1. Overview
      • 8.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.2.7. Canada
      • 8.2.7.1. Overview
      • 8.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.3. Europe
    • 8.3.1. Overview
    • 8.3.2. Key Manufacturers in Europe
    • 8.3.3. Europe Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.3.4. Europe Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 8.3.5. Europe Market Size and Forecast, By Pharmacological Class, 2015 - 2026 (US$ Million)
    • 8.3.6. Germany
      • 8.3.6.1. Overview
      • 8.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.3.7. Italy
      • 8.3.7.1. Overview
      • 8.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.3.8. United Kingdom
      • 8.3.8.1. Overview
      • 8.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.3.9. France
      • 8.3.9.1. Overview
      • 8.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.3.10. Rest of Europe
      • 8.3.10.1. Overview
      • 8.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.4. Asia Pacific (APAC)
    • 8.4.1. Overview
    • 8.4.2. Key Manufacturers in Asia Pacific
    • 8.4.3. Asia Pacific Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.4.4. Asia Pacific Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 8.4.5. Asia Pacific Market Size and Forecast, By Pharmacological Class, 2015 - 2026 (US$ Million)
    • 8.4.6. India
      • 8.4.6.1. Overview
      • 8.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.4.7. China
      • 8.4.7.1. Overview
      • 8.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.4.8. Japan
      • 8.4.8.1. Overview
      • 8.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.4.9. South Korea
      • 8.4.9.1. Overview
      • 8.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.4.10. Rest of APAC
      • 8.4.10.1. Overview
      • 8.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.5. Latin America
    • 8.5.1. Overview
    • 8.5.2. Key Manufacturers in Latin America
    • 8.5.3. Latin America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.5.4. Latin America Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 8.5.5. Latin America Market Size and Forecast, By Pharmacological Class, 2015 - 2026 (US$ Million)
    • 8.5.6. Brazil
      • 8.5.6.1. Overview
      • 8.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.5.7. Mexico
      • 8.5.7.1. Overview
      • 8.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.5.8. Argentina
      • 8.5.8.1. Overview
      • 8.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.5.9. Rest of LATAM
      • 8.5.9.1. Overview
      • 8.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Overview
    • 8.6.2. Key Manufacturers in Middle East and Africa
    • 8.6.3. Middle East and Africa Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.6.4. Middle East and Africa Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 8.6.5. Middle East and Africa Market Size and Forecast, By Pharmacological Class, 2015 - 2026 (US$ Million)
    • 8.6.6. Saudi Arabia
      • 8.6.6.1. Overview
      • 8.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.6.7. United Arab Emirates
      • 8.6.7.1. Overview
      • 8.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

9. KEY VENDOR ANALYSIS

  • 9.1. Bayer Healthcare
    • 9.1.1. Company Snapshot
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Strategic Initiatives
  • 9.2. Novartis AG
  • 9.3. Prometheus Labs
  • 9.4. Eisai Co., Ltd.
  • 9.5. Bristol-Myers Squibb
  • 9.6. Genentech (Roche)
  • 9.7. Exelixis, Inc.
  • 9.8. Pfizer, Inc.

10. 360 DEGREE ANALYSTVIEW

11. APPENDIX

  • 11.1. Research Methodology
  • 11.2. References
  • 11.3. Abbreviations
  • 11.4. Disclaimer
  • 11.5. Contact Us
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.